PRODUCT
LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial
LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential
XyloCor Therapeutics Secures $67.5 Million in Series B Funding to Advance Cardiovascular Gene Therapy
XyloCor Therapeutics, Series B funding, cardiovascular gene therapy, XC001, refractory angina, CABG, clinical trials
Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular
Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology
Regeneron Acquires UK-Based Eye Drug Developer Oxular
Regeneron, Oxular, eye drug development, retinal therapeutics, acquisition
FDA Approves ALYFTREK, a Next-Generation CFTR Modulator for Cystic Fibrosis Treatment
ALYFTREK, cystic fibrosis, CFTR modulator, FDA approval, once-daily treatment, Vertex Pharmaceuticals
Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease
Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy
Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion
Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition
iTeos Therapeutics Deprioritizes Inupadenant Despite Encouraging Phase 2 Data in NSCLC
iTeos Therapeutics, Inupadenant, Adenosine A2A Receptor Antagonist, NSCLC, Phase 2 Trial, Deprioritization
Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks
Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO
uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130
uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)